{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:47:47Z","timestamp":1794512867506,"version":"4.9.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>In patients with paroxysmal nocturnal hemoglobinuria (PNH), the complement component 5 (C5) inhibitors ravulizumab and eculizumab control terminal complement activity and intravascular hemolysis, which are drivers of morbidity and mortality. During C5 inhibitor treatment, ongoing C3 fragment deposition on surviving PNH red blood cells may cause clinically significant extravascular hemolysis (csEVH) in some patients. csEVH is not thought to be life threatening but may cause symptomatic anemia and need for transfusion. This post hoc analysis of studies 301 (NCT02946463) and 302 (NCT03056040) evaluated the prevalence of csEVH (symptomatic anemia [hemoglobin levels &amp;lt;9.5 g\/dL] with absolute reticulocyte count \u2265120 \u00d7 109\/L) in adult patients with PNH treated with ravulizumab or eculizumab for 6 months (183 days). The association between csEVH and fatigue (measured using the Functional Assessment of Chronic Illness Therapy - Fatigue [FACIT-F] scale) was also evaluated in study 302 patients with stable disease. On day 183 of studies 301 and 302, csEVH prevalence was 23.2% (29\/125) and 20.2% (19\/94) with ravulizumab and 24.8% (30\/121) and 21.3% (20\/94) with eculizumab, respectively. All patients in study 302 with csEVH experienced fatigue, which was mostly mild (ravulizumab, 79%; eculizumab, 65%) or moderate (ravulizumab, 21%; eculizumab, 30%). FACIT-F scores remained stable from baseline (ravulizumab, 42.2; eculizumab, 38.3) to day 183 (ravulizumab, 44.3; eculizumab, 38.3), close to general population normative values. This analysis demonstrated that csEVH affected 20% to 25% of patients with PNH, most of whom experienced mild fatigue, with fatigue remaining stable during treatment. Ravulizumab and eculizumab continue to provide benefit to adults with PNH with csEVH.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015490","type":"journal-article","created":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T15:06:01Z","timestamp":1745507161000},"page":"4936-4945","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":12,"title":["Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin G.","family":"Kulasekararaj","sequence":"first","affiliation":[{"name":"1Hematology Unit, King\u2019s College Hospital, National Institute of Health Research\/Wellcome King\u2019s Clinical Research Facility, King\u2019s College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-4166","authenticated-orcid":false,"given":"Jong Wook","family":"Lee","sequence":"additional","affiliation":[{"name":"2Division of Hematology-Oncology, Hanyang University Seoul Hospital, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2089-8650","authenticated-orcid":false,"given":"Christopher J.","family":"Patriquin","sequence":"additional","affiliation":[{"name":"3Division of Medical Oncology and Hematology, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline I.","family":"Piatek","sequence":"additional","affiliation":[{"name":"4Division of Hematology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4414-7699","authenticated-orcid":false,"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[{"name":"5Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilma","family":"Barcellini","sequence":"additional","affiliation":[{"name":"6Department of Hematology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-1255","authenticated-orcid":false,"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-ichi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"7Department of Hematology and Oncology, Graduate School of Medicine, Osaka University, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Yu","sequence":"additional","affiliation":[{"name":"8Alexion, AstraZeneca Rare Disease, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mahdi","sequence":"additional","affiliation":[{"name":"8Alexion, AstraZeneca Rare Disease, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Peffault de Latour","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Bone Marrow Transplantation, Saint-Louis Hospital, Assistance Publique-H\u00f4pitaux de Paris, Universit\u00e9 Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"2025101409364476000_bib1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fimmu.2019.01157","article-title":"Anti-complement treatment for paroxysmal nocturnal hemoglobinuria: time for proximal complement inhibition? A position paper from the SAAWP of the EBMT","volume":"10","author":"Risitano","year":"2019","journal-title":"Front Immunol"},{"issue":"2","key":"2025101409364476000_bib2","first-page":"205","article-title":"Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents","volume":"2","author":"Risitano","year":"2008","journal-title":"Biologics"},{"issue":"18","key":"2025101409364476000_bib3","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2014-02-522128","article-title":"Paroxysmal nocturnal hemoglobinuria","volume":"124","author":"Brodsky","year":"2014","journal-title":"Blood"},{"key":"2025101409364476000_bib4","doi-asserted-by":"crossref","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","article-title":"Paroxysmal nocturnal haemoglobinuria","volume":"3","author":"Hill","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2025101409364476000_bib5","unstructured":"Soliris\u00ae. Prescribing information. US Food and Drug Administration; 2019. Accessed 1 May 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf."},{"key":"2025101409364476000_bib6","unstructured":"Ultomiris\u00ae. Prescribing information. US Food and Drug Administration; 2022. Accessed 1 May 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761108s023lbl.pdf."},{"issue":"4","key":"2025101409364476000_bib7","doi-asserted-by":"crossref","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: a novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PLoS One"},{"issue":"23","key":"2025101409364476000_bib8","doi-asserted-by":"crossref","first-page":"4777","DOI":"10.1182\/blood.V126.23.4777.4777","article-title":"First in human single-ascending dose study: safety, biomarker, pharmacokinetics and exposure-response relationships of ALXN1210, a humanized monoclonal antibody to C5, with marked half-life extension and potential for significantly longer dosing intervals","volume":"126","author":"Sahelijo","year":"2015","journal-title":"Blood"},{"issue":"6","key":"2025101409364476000_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"6","key":"2025101409364476000_bib10","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","article-title":"Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"issue":"suppl 3","key":"2025101409364476000_bib11","doi-asserted-by":"crossref","first-page":"e6327336","DOI":"10.1097\/01.HS9.0000969992.63273.36","article-title":"P772: long-term ravulizumab treatment in complement inhibitor-experienced patients with PNH provides durable control of intravascular hemolysis with low incidence of major adverse vascular events and death","volume":"7","author":"Kulasekararaj","year":"2023","journal-title":"Hemasphere"},{"issue":"12","key":"2025101409364476000_bib12","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1182\/blood.2023021762","article-title":"Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria","volume":"143","author":"Kelly","year":"2024","journal-title":"Blood"},{"issue":"5","key":"2025101409364476000_bib13","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/ejh.14080","article-title":"Long-term effectiveness of eculizumab: data from the International PNH Registry","volume":"111","author":"Terriou","year":"2023","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025101409364476000_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/ejh.13773","article-title":"Effect of eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria with or without high disease activity: real-world findings from the International Paroxysmal Nocturnal Hemoglobinuria Registry","volume":"109","author":"H\u00f6chsmann","year":"2022","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025101409364476000_bib15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ejh.13783","article-title":"Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies","volume":"109","author":"Kulasekararaj","year":"2022","journal-title":"Eur J Haematol"},{"issue":"3","key":"2025101409364476000_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/ejh.13564","article-title":"One-year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab","volume":"106","author":"Kulasekararaj","year":"2021","journal-title":"Eur J Haematol"},{"key":"2025101409364476000_bib17","doi-asserted-by":"crossref","first-page":"2040620720966137","DOI":"10.1177\/2040620720966137","article-title":"One-year efficacy and safety of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria naive to complement inhibitor therapy: open-label extension of a randomized study","volume":"11","author":"Schrezenmeier","year":"2020","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"2025101409364476000_bib18","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/ajh.24278","article-title":"Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: a treatment versus no-treatment study","volume":"91","author":"Loschi","year":"2016","journal-title":"Am J Hematol"},{"key":"2025101409364476000_bib19","doi-asserted-by":"crossref","first-page":"20406207221091046","DOI":"10.1177\/20406207221091046","article-title":"The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria","volume":"13","author":"Kulasekararaj","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"2025101409364476000_bib20","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","article-title":"Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab","volume":"113","author":"Risitano","year":"2009","journal-title":"Blood"},{"issue":"7","key":"2025101409364476000_bib21","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1080\/17512433.2022.2109462","article-title":"The role of the alternative pathway in paroxysmal nocturnal hemoglobinuria and emerging treatments","volume":"15","author":"Lee","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"1","key":"2025101409364476000_bib22","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/ejh.12021","article-title":"Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria","volume":"90","author":"DeZern","year":"2013","journal-title":"Eur J Haematol"},{"key":"2025101409364476000_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2147\/JBM.S339660","article-title":"Managing fatigue in patients with paroxysmal nocturnal hemoglobinuria: a patient-focused perspective","volume":"13","author":"Fattizzo","year":"2022","journal-title":"J Blood Med"},{"key":"2025101409364476000_bib24","first-page":"100224","article-title":"Even mild hemolysis in paroxysmal nocturnal hemoglobinuria could severely compromise the quality of life due to long-term sustained intolerant fatigue [published correction appears in Leuk Res Rep. 2022;17:100309]","volume":"14","author":"Sakai","year":"2020","journal-title":"Leuk Res Rep"},{"issue":"12","key":"2025101409364476000_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N Engl J Med"},{"issue":"1","key":"2025101409364476000_bib26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00277-023-05483-0","article-title":"Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria","volume":"103","author":"Schrezenmeier","year":"2024","journal-title":"Ann Hematol"},{"issue":"12","key":"2025101409364476000_bib27","doi-asserted-by":"crossref","first-page":"e955","DOI":"10.1016\/S2352-3026(23)00315-0","article-title":"Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial","volume":"10","author":"Lee","year":"2023","journal-title":"Lancet Haematol"},{"key":"2025101409364476000_bib28","unstructured":"EORTC\n          . EORTC QLQ-C30 scoring manual. Updated 2001. Accessed 7 March 2025. https:\/\/www.eortc.org\/app\/uploads\/sites\/2\/2018\/02\/SCmanual.pdf."},{"issue":"7","key":"2025101409364476000_bib29","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","article-title":"Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry","volume":"99","author":"Schrezenmeier","year":"2020","journal-title":"Ann Hematol"},{"issue":"3","key":"2025101409364476000_bib30","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06554.x","article-title":"Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria","volume":"137","author":"Hill","year":"2007","journal-title":"Br J Haematol"},{"issue":"2","key":"2025101409364476000_bib31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1002\/cam4.1953","article-title":"Fatigue, symptom burden, and health-related quality of life in patients with myelodysplastic syndrome, aplastic anemia, and paroxysmal nocturnal hemoglobinuria","volume":"8","author":"Escalante","year":"2019","journal-title":"Cancer Med"},{"issue":"suppl 12-b","key":"2025101409364476000_bib32","first-page":"S8","article-title":"Paroxysmal nocturnal hemoglobinuria: patient journey and burden of disease","volume":"26","author":"Bektas","year":"2020","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"2025101409364476000_bib33","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General population norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"issue":"1","key":"2025101409364476000_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s41687-023-00609-4","article-title":"Clinically important change for the FACIT-Fatigue scale in paroxysmal nocturnal hemoglobinuria: a derivation from international PNH registry patient data","volume":"7","author":"Cella","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"2","key":"2025101409364476000_bib35","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00277-021-04715-5","article-title":"The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey","volume":"101","author":"Dingli","year":"2022","journal-title":"Ann Hematol"},{"issue":"1","key":"2025101409364476000_bib36","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12889-017-4623-y","article-title":"Fatigue in the general population- associations to age, sex, socioeconomic status, physical activity, sitting time and self-rated health: the northern Sweden MONICA study 2014","volume":"17","author":"Engberg","year":"2017","journal-title":"BMC Public Health"},{"key":"2025101409364476000_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2018.11.024","article-title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canada and the Unites States","volume":"107","author":"Nolte","year":"2019","journal-title":"Eur J Cancer"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4936\/2414531\/blooda_adv-2024-015490-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/19\/4936\/2414531\/blooda_adv-2024-015490-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T13:38:29Z","timestamp":1760449109000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/19\/4936\/537000\/Characterizing-clinically-significant"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":37,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2025,10,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015490","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,14]]},"published":{"date-parts":[[2025,9,29]]}}}